ACAD Q2 2019 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$83M+45.8% YoY

Gross Profit

$78M94.0% margin

Operating Income

-$57M-68.6% margin

Net Income

-$55M-66.0% margin

EPS (Diluted)

$-0.38

QoQ Revenue Growth

+32.2%

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$38M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$461M

Total Liabilities

$72M

Stockholders' Equity

$389M

Cash & Equivalents

$74M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$83M	$57M	+45.8%
Gross Profit	$78M	$52M	+50.4%
Operating Income	-$57M	-$64M	+10.9%
Net Income	-$55M	-$63M	+13.2%